Sylvant(siltuximab)
Sylvant (siltuximab) is an antibody pharmaceutical. Siltuximab was first approved as Sylvant on 2014-04-23. It is used to treat castleman disease in the USA. It has been approved in Europe to treat castleman disease. The pharmaceutical is active against interleukin-6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Sylvant
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| sylvant | Biologic Licensing Application | 2024-08-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| castleman disease | EFO_1001332 | D005871 | D47.Z2 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
siltuximab, Sylvant, EUSA Pharma (UK) Limited | |||
| 2121-04-23 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2860 | Injection, siltuximab, 10 mg |
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | — | 1 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | 1 | — | — | 1 |
| Respiratory tract diseases | D012140 | — | — | — | — | 1 | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 1 | — | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
| Chronic pain | D059350 | — | — | — | 1 | — | — | — | 1 |
| Neurilemmoma | D009442 | EFO_0000693 | — | — | 1 | — | — | — | 1 |
| Castleman disease | D005871 | EFO_1001332 | D47.Z2 | — | 1 | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cytokine release syndrome | D000080424 | — | D89.83 | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Siltuximab |
| INN | siltuximab |
| Description | Siltuximab (chimeric mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743070 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09036 |
| UNII ID | T4H8FMA7IM (ChemIDplus, GSRS) |
Target
Agency Approved
IL6
IL6
Organism
Homo sapiens
Gene name
IL6
Gene synonyms
IFNB2
NCBI Gene ID
Protein name
interleukin-6
Protein synonyms
B-cell differentiation factor, B-cell stimulatory factor 2, BSF-2, CDF, CTL differentiation factor, Hybridoma growth factor, IFN-beta-2, Interferon beta-2, interleukin BSF-2
Uniprot ID
Mouse ortholog
Il6 (16193)
interleukin-6 (P08505)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,386 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
472 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use